|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 329.89 USD | -3.02% |
|
-4.51% | +26.57% |
| 12-03 | Amgen Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-03-2025 01:45 PM | |
| 12-03 | Amgen Inc. Presents at Evercore 8th Annual Healthcare Conference, Dec-03-2025 10:00 AM |
| Capitalization | 178B 153B 143B 133B 246B 15,987B 268B 1,673B 646B 7,551B 667B 652B 27,608B | P/E ratio 2025 * |
25.2x | P/E ratio 2026 * | 23.9x |
|---|---|---|---|---|---|
| Enterprise value | 222B 191B 179B 167B 308B 19,999B 335B 2,093B 808B 9,445B 834B 816B 34,536B | EV / Sales 2025 * |
6.12x | EV / Sales 2026 * | 5.89x |
| Free-Float |
99.85% | Yield 2025 * |
2.9% | Yield 2026 * | 3.06% |
Last Transcript: Amgen Inc.
| 1 day | -3.02% | ||
| 1 week | -4.51% | ||
| Current month | -4.51% | ||
| 1 month | +4.53% | ||
| 3 months | +16.31% | ||
| 6 months | +13.63% | ||
| Current year | +26.57% |
| 1 week | 328.63 |  | 346.38 |
| 1 month | 319.54 | | 346.38 |
| Current year | 257.05 | | 346.38 |
| 1 year | 253.3 | | 346.38 |
| 3 years | 211.71 | | 346.85 |
| 5 years | 198.64 | | 346.85 |
| 10 years | 133.64 | | 346.85 |
| Manager | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CEO | Chief Executive Officer | 62 | 30/04/2012 |
Peter Griffith
DFI | Director of Finance/CFO | 66 | 31/12/2019 |
Esteban Santos
COO | Chief Operating Officer | 58 | 24/07/2016 |
| Director | Title | Age | Since |
|---|---|---|---|
Robert Bradway
CHM | Chairman | 62 | 31/12/2012 |
Tyler Jacks
BRD | Director/Board Member | 64 | 31/12/2011 |
Robert Eckert
BRD | Director/Board Member | 70 | 31/12/2011 |
| Name | Weight | AuM | Varia. Jan 1. | Investor |
|---|---|---|---|---|
 | 5.08% | 135 M€ | +8.98% | - |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -3.02% | -4.51% | +21.03% | +16.45% | 178B | |
| -0.41% | -6.06% | +22.21% | +174.14% | 905B | |
| -0.27% | -2.41% | +35.24% | +14.67% | 487B | |
| -1.15% | -0.71% | +28.32% | +38.09% | 400B | |
| +0.26% | +1.14% | +20.97% | +1.87% | 330B | |
| +0.58% | -2.73% | +27.58% | +21.90% | 281B | |
| +0.19% | +2.49% | +19.23% | +25.56% | 255B | |
| -1.16% | -4.87% | -3.27% | -8.45% | 248B | |
| +1.24% | -2.33% | -60.59% | -30.82% | 214B | |
| -1.14% | -3.67% | +31.57% | +37.81% | 150B | |
| Average | -0.49% | -2.37% | +14.23% | +29.12% | 344.69B | |
| Weighted average by Cap. | -0.40% | -2.83% | +18.23% | +56.02% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 36.33B 31.23B 29.25B 27.27B 50.36B 3,269B 54.78B 342B 132B 1,544B 136B 133B 5,646B | 36.85B 31.68B 29.67B 27.66B 51.09B 3,317B 55.57B 347B 134B 1,566B 138B 135B 5,727B |
| Net income | 7.34B 6.31B 5.91B 5.51B 10.18B 661B 11.08B 69.18B 26.71B 312B 27.57B 26.98B 1,141B | 7.37B 6.34B 5.94B 5.54B 10.22B 664B 11.12B 69.46B 26.82B 313B 27.68B 27.09B 1,146B |
| Net Debt | 44.57B 38.32B 35.89B 33.46B 61.79B 4,012B 67.21B 420B 162B 1,895B 167B 164B 6,928B | 39.27B 33.76B 31.63B 29.48B 54.45B 3,535B 59.22B 370B 143B 1,669B 147B 144B 6,104B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 05/12/25 | 329.89 $ | -3.02% | 2,897,992 |
| 04/12/25 | 340.16 $ | -1.52% | 3,695,846 |
| 03/12/25 | 345.42 $ | +2.09% | 2,839,394 |
| 02/12/25 | 338.36 $ | +0.26% | 2,446,819 |
| 01/12/25 | 337.49 $ | -2.31% | 2,384,122 |
Delayed Quote Nasdaq, December 05, 2025 at 09:00 pm
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- AMGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition